ClinicalTrials.gg
Not yet recruitingNCT07529015PAS-MCIUpdated Nov 19, 2026

Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI

An interventional study of Plase-Locked Acoustic Stimulation during slow-wave sleep and Phase-locked acoustic stimulation-Sham condition in Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) Amnestic and Cognitively Unimpaired, sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida). Not yet recruiting at 1 site in Spain. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) · Not applicable, Interventional, and Other

How we know

Updated Nov 19, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Planned enrollment
168th of 240
114 · median 258
Started
2026
with 18 others
No phase
66 of 279
17 open now
Primary completion
2027-12
later than 42 of 79 live
Registered
269th of 279
by date

Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 168th largest by planned enrollment of the 240 interventional ones that give a count, is one of 19 that started in 2026, is one of 66 with no phase, reaches primary completion later than 42 of the 79 other live ones, and was the 269th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether acoustic stimulation during sleep can enhance slow-wave sleep (SWS), improve cognitive function, and reduce AD-related pathology in individuals with mild cognitive impairment (MCI), compared with cognitively healthy participants.

The main questions it aims to answer are:

  1. Does acoustic stimulation increase SWS (e.g., slow oscillation and sleep spindle activity) in individuals with MCI?
  2. Does enhancing SWS lead to improvements in memory and cognitive performance?
  3. Does acoustic stimulation influence plasma p-tau217 levels as a marker of underlying Alzheimer's disease pathology? Researchers will compare participants receiving acoustic stimulation during sleep with those not receiving stimulation to evaluate its effects on sleep architecture, cognition, and plasma biomarkers.

Participants will:

  • Undergo sleep recordings to assess sleep architecture, including SWS, slow oscillations, and sleep spindles
  • Receive acoustic stimulation during sleep across multiple nights
  • Complete cognitive assessments, particularly memory-related tasks
  • Provide blood samples to measure plasma p-tau217 levels
  • Provide clinical and demographic information for analysis
03

Conditions studied

  • Alzheimer's Disease (AD)
  • Mild Cognitive Impairment (MCI) Amnestic
  • Cognitively Unimpaired

Keywords

  • Alzheimer's disease
  • acoustic stimulation
  • declarative memory
  • amnestic mild cognitive impairment
  • sleep spindle
  • episodic memory
  • sleep EEG
  • slow-wave sleep
  • p-tau217
  • slow oscillation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of aMCI according to the NIA-AA criteria (Albert et al., 2011) and positive state of plasma p-tau217.
  • Diagnosis of aMCI according to the NIA-AA criteria (Albert et al., 2011) and negative state of plasma p-tau217 for aMCI negative group.
  • Cognitively unimpaired older subjects aged ≥ 65 years, ≥28, and negative for plasma p-tau217.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of dementia due to AD or any other type of dementia.
  • Presence of any diagnosed sleep disorder such as narcolepsy, severe insomnia, severe obstructive sleep apnea, or severe chronic lack of sleep.
  • Hearing problems.
  • Analphabet individuals.
  • Comorbidities such as cancer, severe depression, severe renal or hepatic insufficiency, history of seizures, and severe cardiac or respiratory failure.
  • Alcohol and substance abuse.
  • Magnetic resonance imaging (MRI) evidence of stroke, hydrocephalus, a space-occupying lesion, or any central nervous system disease.
  • Existence of untreated (or treated for less than 3 months prior to the screening visit) vitamin B12 or folate deficiency.
  • Presence of untreated thyroid disease.
  • Use of betablockers, antidepressants, neuroleptics, and hypnotics, within 15 days before conducting polysomnography.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Real-PLAS

    Receiving phase-locked acoustic stimulation as an intervention

    Device: Plase-Locked Acoustic Stimulation during slow-wave sleep

  • Sham comparator
    Sham-PLAS

    Will have the same montage as real-PLAS, but no stimulation will be produced

    Device: Phase-locked acoustic stimulation-Sham condition

Interventions

  • DevicePlase-Locked Acoustic Stimulation during slow-wave sleep

    Participants will wear a mobile, wearable EEG device during sleep. Sleep will be recorded using EEG, and an algorithm will detect slow oscillations (SOs; \>1 Hz). In the real-PLAS arm, acoustic stimulation will be applied in phase with the up-state of these slow oscillations. Specifically, the algorithm will detect each SO and trigger brief pink-noise bursts synchronized with the up-state phase, ensuring phase-locked acoustic stimulation (PLAS) is delivered precisely to enhance slow-wave activity.

    Also known as: Closed-loop acoustic stimulation, Closed-loop auditive stimulation

  • DevicePhase-locked acoustic stimulation-Sham condition

    Participants will have the same setup as in the real-PLAS arm, wearing a mobile, wearable EEG device during sleep. Sleep will be recorded using EEG, and an algorithm will detect slow oscillations (SOs; \>1 Hz). No acoustic stimulation will be applied in the sham-PLAS arm.

06

What researchers measure

Primary outcomes

  1. Impact on SWS: SO and sleep spindle density

    Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the density of both features (expressed as counts per 30 seconds). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.

    Time frame: 14 nights

  2. Impact on SWS: SO and sleep spindle duration

    Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the duration of both features (expressed in seconds). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.

    Time frame: 14 nights

  3. Impact on SWS: SO and sleep spindle peak-to-peak amplitude

    Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the peak-to-peak amplitude of both features (expressed in µV).Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.

    Time frame: 14 nights

  4. Impact on SWS: SO and sleep spindle peak power frequency

    Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the peak power frequency of each feature (expressed in Hz). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.

    Time frame: 14 nights

  5. Impact on SWS: SO and sleep spindle power

    Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the power of both features (expressed in µV2). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.

    Time frame: 14 nights

  6. Impact on declarative memory consolidation: correct performance in the Verbal Paired Associates test

    The impact of multi-night PLAS on declarative memory performance in the study population will be assessed using the Verbal Paired Associates (VPA) test. Performance will be quantified as the number of correctly recalled word pairs. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.

    Time frame: Up to 3 months after intervention

  7. Impact on procedural memory consolidation: correct performance in the Motor Sequence Typing task

    The impact of multi-night PLAS on procedural memory performance in the study population will be assessed using the Motor Sequence Typing task (MST). Performance will be quantified as the number of correctly executed sequences (i.e., keypresses) per trial. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.

    Time frame: Up to 3 months after intervention

  8. Impact on procedural memory consolidation: incorrect performance in the Motor Sequence Typing task

    The impact of multi-night PLAS on procedural memory performance in the study population will be assessed using the Motor Sequence Typing task (MST). Performance will be quantified as the number of incorrectly executed sequences (i.e., keypresses) per trial. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.

    Time frame: Up to 3 months after intervention

  9. Impact on procedural memory consolidation: total attempt performance in the Motor Sequence Typing task

    The impact of multi-night PLAS on procedural memory performance in the study population will be assessed using the Motor Sequence Typing Task (MST). Performance will be quantified as the total number of executed sequences (i.e., keypresses) per trial. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.

    Time frame: Up to 3 months after intervention

  10. Impact on p-tau217

    Post-intervention plasma levels of p-tau217(pg/mL), including follow-up assessments, will be measured in the study population and compared with baseline values as well as with the sham group.

    Time frame: Up to 3 months after intervention

Secondary outcomes

  1. Effect on GFAP and NfL

    Post-intervention plasma levels of Glial fibrillary acidic protein (GFAP, pg/mL) and neurofilament light (NfL, pg/mL), including follow-up assessments, will be measured in the study population and compared with baseline values as well as with the sham group.

    Time frame: Up to 3 months after intervention

07

Study locations

1 site
  • Hospital Universitari Santa Maria de Lleida
    Lleida, Catalonia 25198, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Apr 2026 → Dec 2026 and primary completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 14, 2026
StartEst.
Dec 2026was Apr 2026
Primary completionEst.
Dec 2027was Sep 2027
CompletionEst.
Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Dec 2026
Nov 19, 2026
Primary completion
Sep 2027→Dec 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Apr 2026→Dec 2026
    Primary completion Sep 2027→Dec 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07529015
Lead sponsor
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)
Responsible party
Farida Dakterzada (Principal Investigator, Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)) — Principal investigator
First posted
Apr 14, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Farida Dakterzada, PhD
Contact
farida.dakterzada@udl.cat
+34-973702413
Gerard Piñol-Ripoll, MD, PhD
Contact
gerard_437302@hotmail.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion